Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a report published on Monday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

A number of other analysts have also recently issued reports on CLLS. JMP Securities reissued a market outperform rating and set a $6.00 target price on shares of Cellectis in a research note on Friday, May 31st. Oppenheimer reduced their price target on shares of Cellectis from $11.00 to $10.00 and set an outperform rating for the company in a report on Wednesday, June 12th.

Cellectis Price Performance

CLLS opened at $2.30 on Monday. The stock has a market cap of $127.84 million, a P/E ratio of -1.78 and a beta of 3.10. Cellectis has a 12 month low of $0.96 and a 12 month high of $3.77. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.39. The company has a fifty day simple moving average of $2.13 and a 200 day simple moving average of $2.46.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05. The firm had revenue of $9.50 million during the quarter, compared to analysts’ expectations of $6.00 million. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. On average, research analysts expect that Cellectis will post -0.54 EPS for the current year.

Institutional Investors Weigh In On Cellectis

Hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd acquired a new position in Cellectis during the 2nd quarter worth approximately $29,000. Principal Financial Group Inc. raised its holdings in shares of Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares during the last quarter. Baillie Gifford & Co. lifted its position in shares of Cellectis by 1.3% in the first quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock worth $2,192,000 after purchasing an additional 10,605 shares in the last quarter. Finally, Long Focus Capital Management LLC lifted its position in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares in the last quarter. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.